El interés en corto de CytoSorbents da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de CytoSorbents. Los datos de interés en corto se actualizan cada dos semanas.

CytoSorbents (NASDAQ:CTSO) Bolsa, Informe de interés en corto

CYTOSORBENTS CORP

CytoSorbents

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

CytoSorbents Corp

<h3>Gainers</h3>
<ul>
<li><strong>Sonnet BioTherapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock moved upwards by 82.6% to $2.21 during Wednesday's regular session. The market value of their outstanding shares is at $3.8 million. </li>
<li><strong>Lixte Biotechnology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock moved upwards by 49.15% to $1.76. The market value of their outstanding shares is at $3.2 million. </li>
<li><strong>Eyenovia</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares moved upwards by 40.9% to $14.88. The market value of their outstanding shares is at $53.9 million. </li>
<li><strong>NeOnc Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) stock increased by 31.34% to $4.4. The company's market cap stands at $63.7 million. </li>
<li><strong>Nutriband</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares moved upwards by 27.93% to $10.26. The market value of their outstanding shares is at $89.2 million. </li>
<li><strong>Windtree Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares moved upwards by 25.39% to $0.69. The company's market cap stands at $2.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Centene</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares decreased by 39.6% to $34.19 during Wednesday's regular session. The market value of their outstanding shares is at $28.1 billion. </li>
<li><strong>Mustang Bio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock decreased by 38.44% to $1.26. The company's market cap stands at $8.9 million. </li>
<li><strong>Regencell Bioscience</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 27.37% to $10.61. The company's market cap stands at $7.2 billion. As per the news, the H1 earnings report came out 2 days ago. </li>
<li><strong>CytoSorbents</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) stock declined by 25.82% to $0.96. The market value of their outstanding shares is at $80.7 million. </li>
<li><strong>Cyclacel Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 20.43% to $0.27. The market value of their outstanding shares is at $7.9 million. </li>
<li><strong>Molina Healthcare</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares declined by 20.18% to $244.5. The market value of their outstanding shares is at $16.6 billion.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

CTSO

CYCC

EYEN

LIXT

MBIO

NTHI

NTRB

SONN

WINT

12 Health Care Stocks Moving In Wednesday's Intraday Session

News

CytoSorbents Pursues Supervisory Review With US FDA And Reconsideration With Health Canada For DrugSorb-ATR Marketing Applications

<p>Ratings for CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for CytoSorbents, revealing an average target of $7.0, a high estimate of $10.00, and a low estimate of $1.00. Consistency is reflected as the current average remains at the same level as the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1750856413_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive CytoSorbents is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Sean Lee</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$1.00</td>
<td>$1.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Sean Lee</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$1.00</td>
<td>$1.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CytoSorbents. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CytoSorbents compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of CytoSorbents's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CytoSorbents's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CTSO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on CytoSorbents analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>About CytoSorbents</h2>
<p>CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.</p>
<h3>Financial Insights: CytoSorbents</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, CytoSorbents faced challenges, resulting in a decline of approximately <strong>-2.92%</strong> in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> CytoSorbents's net margin is impressive, surpassing industry averages. With a net margin of <strong>-16.94%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> CytoSorbents's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-11.53%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> CytoSorbents's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-3.01%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> CytoSorbents's debt-to-equity ratio surpasses industry norms, standing at <strong>1.85</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Deep Dive Into CytoSorbents Stock: Analyst Perspectives (6 Ratings)

<p>D. Boral Capital  analyst Jason Kolbert   maintains CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy and maintains $10 price target.</p>


Price Target

D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target

<p><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455394-1&amp;h=3327837114&amp;u=http%3A%2F%2Fwww.cytosorbents.com%2F&amp;a=CytoSorbents+Corporation">CytoSorbents Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for supervisory review (administrative appeal) with the U.S. Food and Drug Administration (FDA) under 21 CFR 10.75, of the De Novo Denial Letter issued on April 25, 2025 for CytoSorbents' DrugSorb-ATR Device, &nbsp;(the denial letter).&nbsp; DrugSorb-ATR, which previously received Breakthrough Device Designation from the FDA, is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within two days of stopping the antiplatelet drug Brilinta&#xAE; (ticagrelor, AstraZeneca), a commonly used blood thinner.</p>
<p>The denial letter identified remaining deficiencies that must be addressed before the De Novo Request can be granted and the device authorized for U.S. commercialization. &nbsp;In response, the Company engaged with the FDA review team to clarify and discuss the remaining deficiencies.&nbsp; After careful consultation with its regulatory counsel and advisors, the Company determined that a supervisory review through the administrative appeals process was the best path to resolve the remaining deficiencies.</p>
<p>The administrative appeals process allows the Company to engage with upper management of FDA's Center for Devices and Radiological Health (CDRH) in a prescribed procedure that includes a formal hearing, with a final decision typically issued approximately 60 days after the appeal is filed.</p>
<p>CytoSorbents' DrugSorb-ATR application with Health Canada remains under advanced review.&nbsp; As previously disclosed, Health Canada indicated that application reviews are delayed beyond their target Market Authorization Times (MAT) due to a backlog but is committed to issuing a decision at the earliest opportunity.&nbsp; The Company remains confident in receiving a final regulatory decision in 2025.</p>


CytoSorbents Files Request For Supervisory Review With FDA Of De Novo Denial Letter Issued For CytoSorbents' DrugSorb-ATR Device

CytoSorbents Initiates Formal Appeal To FDA Over DrugSorb-ATR Denial, Aiming To Address Remaining Deficiencies

<p><i>Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the Blood Thinner, Ticagrelor, with CytoSorbents Therapy</i></p>
<p>PRINCETON, N.J., May 22, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4433823-1&amp;h=2734838480&amp;u=http%3A%2F%2Fwww.cytosorbents.com%2F&amp;a=CytoSorbents+Corporation">CytoSorbents Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today's presentation at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4433823-1&amp;h=2143812866&amp;u=https%3A%2F%2Fwww.pcronline.com%2FCourses%2FEuroPCR%2Fabout%2FWhat-is-EuroPCR&amp;a=EuroPCR+2025"><i>EuroPCR 2025</i></a> of a new contemporary real-world data analysis highlighting the intraoperative use of its technology to significantly reduce the severity of bleeding in urgent coronary artery bypass grafting (CABG) patients on the blood thinner, ticagrelor (Brilinta&#xAE;, AstraZeneca) who had not completed the recommended drug washout period.&nbsp;</p>


CytoSorbents Presents Real-World Analysis At EuroPCR 2025 Showing Reduction In Severe Bleeding And Transfusion Needs In CABG Patients On Blood Thinner, Ticagrelor, With CytoSorbents Therapy

<p>HC Wainwright &amp; Co.  analyst Sean Lee   reiterates CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Neutral and maintains $1 price target.</p>


Reiteration

HC Wainwright & Co. Reiterates Neutral on CytoSorbents, Maintains $1 Price Target

Earnings

ADCT

AEVA

AFCG

ALUR

ARCO

ATER

AYTU

BCDA

BITF

BNGO

The Beachbody Company, Inc. Class A Common Stock

BODI

BOOT

BRTX

BZAI

CAAS

CANG

CCAP

CDXS

CELC

CLBT

CLSD

CREX

CSCO

CSPI

CSWC

DAVA

DERM

DRIO

DYAI

EGAN

ELVA

EPSN

EWCZ

FIHL

FOSL

GCTS

GLBE

GROV

GWRS

HWKN

IBTA

ICCC

INVZ

IREN

ISSC

ITRG

JACK

KARO

KITT

KMDA

KRNT

LAZR

LDTC

LIEN

LIQT

LOCL

LUCD

LUXE

LVLU

MDXH

MGRM

MMYT

NEXN

NSYS

NTWK

NVGS

NYXH

ONCY

PDSB

PYPD

RCAT

RDCM

REKR

RELI

RSKD

SBLK

SCPH

SDHC

SDOT

SDST

SGML

SHIM

Earnings Scheduled For May 14, 2025

<p>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) will release its quarterly earnings report on Wednesday, 2025-05-14. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate CytoSorbents to report an <strong>earnings per share</strong> (EPS) of $-0.08.</p>
<p>The market awaits CytoSorbents's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>In the previous earnings release, the company missed EPS by $0.07, leading to a 0.0% drop in the share price the following trading session.</p>
<p>Here's a look at CytoSorbents's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.07</td>
<td>-0.06</td>
<td>-0.09</td>
<td>-0.12</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.14</td>
<td>-0.04</td>
<td>-0.08</td>
<td>-0.12</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>-18.0%</td>
<td>8.0%</td>
<td>12.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747159308_0.png" alt="eps graph" /></p>
<h3>Performance of CytoSorbents Shares</h3>
<p>Shares of CytoSorbents were trading at $0.8701 as of May 12. Over the last 52-week period, shares are up 4.68%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analyst Opinions on CytoSorbents</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding CytoSorbents.</p>
<p>CytoSorbents has received a total of 4 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $7.75, the consensus suggests a potential 790.7% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Hyperfine, Zynex and Sensus Healthcare, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Hyperfine, with an average 1-year price target of $1.33, suggesting a potential 52.86% upside.</li>
<li>Analysts currently favor an Buy trajectory for Zynex, with an average 1-year price target of $8.12, suggesting a potential 833.23% upside.</li>
<li>Analysts currently favor an Buy trajectory for Sensus Healthcare, with an average 1-year price target of $12.5, suggesting a potential 1336.62% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Hyperfine, Zynex and Sensus Healthcare, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CytoSorbents</td>
<td>Buy</td>
<td>24.52%</td>
<td>$9.40M</td>
<td>-65.41%</td>
</tr>
<tr>
<td>Hyperfine</td>
<td>Buy</td>
<td>-13.59%</td>
<td>$826K</td>
<td>-19.36%</td>
</tr>
<tr>
<td>Zynex</td>
<td>Buy</td>
<td>-42.88%</td>
<td>$18.21M</td>
<td>-36.81%</td>
</tr>
<tr>
<td>Sensus Healthcare</td>
<td>Buy</td>
<td>3.97%</td>
<td>$7.11M</td>
<td>2.81%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>CytoSorbents ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity. Overall, CytoSorbents shows strong revenue growth and gross profit performance compared to its peers, but lags behind in terms of return on equity.</p>
<h3>Get to Know CytoSorbents Better</h3>
<p>CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.</p>
<h3>Unraveling the Financial Story of CytoSorbents</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, CytoSorbents showcased positive performance, achieving a revenue growth rate of <strong>24.52%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-86.16%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-65.41%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> CytoSorbents's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-16.57%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> CytoSorbents's debt-to-equity ratio surpasses industry norms, standing at <strong>2.42</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/CTSO/earnings"><strong>To track all earnings releases for CytoSorbents visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CytoSorbents's Earnings: A Preview

<p>4 analysts have shared their evaluations of CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated CytoSorbents and provided 12-month price targets. The average target is $7.75, accompanied by a high estimate of $10.00 and a low estimate of $1.00. Holding firm without variation, the current average remains at the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746190871_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of CytoSorbents by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Sean Lee</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$1.00</td>
<td>$1.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CytoSorbents. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CytoSorbents compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of CytoSorbents's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CytoSorbents's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CTSO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on CytoSorbents analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering CytoSorbents: A Closer Look</h2>
<p>CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.</p>
<h3>Financial Insights: CytoSorbents</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, CytoSorbents showcased positive performance, achieving a revenue growth rate of <strong>24.52%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> CytoSorbents's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-86.16%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> CytoSorbents's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-65.41%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> CytoSorbents's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-16.57%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> CytoSorbents's debt-to-equity ratio surpasses industry norms, standing at <strong>2.42</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying CytoSorbents: Insights From 4 Analyst Reviews

<h3>Gainers</h3>
<ul>
<li><strong>Polyrizon</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 65.8% to $0.42 during Friday's pre-market session. The company's market cap stands at $16.7 million. </li>
<li><strong>AirSculpt Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares increased by 16.81% to $2.64. The market value of their outstanding shares is at $154.6 million. The company's, Q1 earnings came out today. </li>
<li><strong>American Well</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) shares rose 16.15% to $7.19. The market value of their outstanding shares is at $113.6 million. The company's, Q1 earnings came out yesterday. </li>
<li><strong>ModivCare</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock moved upwards by 15.94% to $1.6. The company's market cap stands at $22.9 million. </li>
<li><strong>Rockwell Medical</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares rose 12.93% to $1.22. The market value of their outstanding shares is at $41.5 million. </li>
<li><strong>Camp4 Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares moved upwards by 12.76% to $2.12. The market value of their outstanding shares is at $42.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>CytoSorbents</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) stock fell 18.8% to $0.82 during Friday's pre-market session. The company's market cap stands at $51.3 million. </li>
<li><strong>Ardelyx</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) stock decreased by 18.65% to $4.45. The company's market cap stands at $1.0 billion. The company's, Q1 earnings came out yesterday. </li>
<li><strong>Healthcare Triangle</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 17.45% to $0.22. The company's market cap stands at $10.0 million. </li>
<li><strong>Tvardi Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVRD#NASDAQ">TVRD</a>) shares fell 17.1% to $21.1. The company's market cap stands at $197.4 million. </li>
<li><strong>Amarin Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock fell 15.76% to $9.25. The market value of their outstanding shares is at $3.8 billion. </li>
<li><strong>Agape ATP</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares declined by 11.97% to $2.06. The market value of their outstanding shares is at $103.0 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AIRS

AMRN

AMWL

ARDX

ATPC

CAMP

HCTI

MODV

PLRZ

RMTI

TVRD

12 Health Care Stocks Moving In Friday's Pre-Market Session

<p><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4418521-1&amp;h=1543242003&amp;u=http%3A%2F%2Fwww.cytosorbents.com%2F&amp;a=CytoSorbents+Corporation">CytoSorbents Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb&#x2122;-ATR, its FDA-designated Breakthrough Device.&nbsp; DrugSorb-ATR is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of stopping the antiplatelet drug Brilinta&#xAE; (ticagrelor, AstraZeneca), a commonly used blood thinner.</p>


CytoSorbents Provides Regulatory Update For Its FDA-Designated Breakthrough Device, DrugSorb-ATR

Health Care

General

CytoSorbents Received $1.7M In Cash Proceeds From The Sale Of Its 2023 And Amended 2022 Net Operating Loss And R&D Tax Credits From The Technology Business Tax Certificate Transfer Program, Sponsored By The New Jersey Economic Development Authority

<p>In the last three months, 4 analysts have published ratings on CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for CytoSorbents, presenting an average target of $10.0, a high estimate of $10.00, and a low estimate of $10.00. This current average has not changed from the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1743516122_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of CytoSorbents among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CytoSorbents. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CytoSorbents compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of CytoSorbents's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CytoSorbents's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CTSO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on CytoSorbents analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know CytoSorbents Better</h2>
<p>CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.</p>
<h3>CytoSorbents: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> CytoSorbents's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>11.08%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> CytoSorbents's net margin is impressive, surpassing industry averages. With a net margin of <strong>-27.1%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> CytoSorbents's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-15.7%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> CytoSorbents's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-4.61%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> CytoSorbents's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.06</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: CytoSorbents In The Eyes Of 4 Experts

<p>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent.  The company reported quarterly sales of $9.200 million which missed the analyst consensus estimate of $10.100 million by 8.91 percent.  This is a 5.75 percent increase over sales of $8.700 million the same period last year.</p>


Earnings Beats

Earnings Misses

CytoSorbents Q4 2024 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $9.200M Miss $10.100M Estimate

Small Cap

Press Releases

CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

CytoSorbents Provides Regulatory Update for DrugSorb-ATR

CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

CytoSorbents to Participate at the Jefferies Global Healthcare Conference

CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR

CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Apyx Medical

HeartBeam

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

CytoSorbents

Interés en corto

CytoSorbents (NASDAQ:CTSO) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL